UK markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3955-0.0125 (-3.06%)
At close: 11:18AM BST
Full screen
Previous close0.4080
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume25,200
Avg. volume2,025
Market cap112,521
Beta (5Y monthly)2.13
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext Paris

    PARIS, May 07, 2024--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA

  • Business Wire

    GenSight Biologics: Annual General Meeting on May 29, 2024

    PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 29, 2024, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.

  • Business Wire

    GenSight Biologics Announces a Successful Offering for an Amount Over €9.2 Million

    PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading of the Company’s shares following the success of its Offering (as defined below), through (i) a capital increase reserved to specialized investors and (ii) a c